1Non-small Cell Lung Cancer Collaborative Group. Chemotherapy innon-small cell lung cancer: a meta-analysis using updated data onindividual patients from 52 randomised clinical trials [ J ]. BMJ,1995, 311: 899-909.
2Fisher MD, D’ Orazio A. Phase II and III trials: comparison of fourchemotherapy regimens in advanced non small cell lung cancer(ECOG 1594) [J]. Clin Lung Cancer, 2000, 2: 21-22.
3Delbaldo C,Michiels S,Syz N,et al. Benefits of adding a drug to asingle-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer A meta-analysis [ J ]. JAMA,2004,292 :470484.
4Park J 0, Ki Sang-Wem, Ahn JS, et al. Phase HI trial of twoversus four additional cycles in patients who are nonprogressive aftertwo cycles of platinum-based chemotherapy in non-small-cell lungcancer[ J]. J Clin Oncol, 2007, 20: 5233-5239.
5Mok TS, Wu YL, Yu CJ,et al. Randomized, placebo-controlled,phase II study of sequential erlotinib and chemotherapy as first-linetreatment for advanced non-small-cell lung cancer [J]. J ClinOncol,2009,27: 5080-5087.
6Hanna N, Shepherd FA, Fossella FV,et al. Randomized phase IEtrial of pemetrexed versus docetaxel in patients with non-small-celllung cancer previously treated with chemotherapy[ J]. J Clin Oncol,2004, 22: 1589-1597.
7Cappuzzo F, Ciuleanu T, Stelmakh L, et al. SATURN: a double-blind ,randomized,phase HI study of maintenance erlotinib versusplacebo following nonprogression with first-line platinum-basedchemotherapy in patients with advanced NSCLC[ J]. J Clin Oncol,2009,27 : 15s, ( suppl; abstr 8001 ).
8Thatcher N,Chang A,Parikh P,et al. gifitinib plus best supportivecare in previously treated patients with refractory advanced NSCLC :result from randomized, placebo-controlled multicenter study [ J ].Lancet, 2005, 366: 1527-1537.
9Shepherd FA, Pereira JR, Ciuleanu T, et al. Erlotinib in previouslytreated non-small cell cancer[ J]. N Eng J Med, 2005,353 : 123-132.
10Gridelli C, Ciardiello F, Feld R, et al. International multicenterrandomized phase DI study of first-line erlotinib ( E) followed bysecond-line cisplatin plus gemcitabine ( CG) versus first-line CGfollowed by second-line E in advanced non-small cell lung cancer(aNSCLC) : The TORCH trial[J]. J Clin Oncol, 2010,28: 15s.
3van Noord JA,Aumann JL,Janssens E,et al.Effects of tiotropium with and without formoterol on airflowobstruction and testing hyperinflation in pa-tients with COPD. Chest . 2006
4Stellman SD,Muscat JE,Thompson S,et al.Risk of squamous cell carcinoma and adenocarcinoma of the lung in relation to lifetime filter cigarette smoking. Cancer . 1997
5Hsieh RK,Lim KH,Kuo HT,et al.Female sex and bronchio-loalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer. Chest . 2005
5Jemal A, Siegel R, Xu J, et al. Cancer Statistics 2010[J]. CA Cancer J Clin, 2010, 60(5): 277-300.
6Mroczko B, Lukaszewicz-Zajac M, Guzifiska-Ustymowicz K, et al. Expression of matrix metalloproteinase-9 in the neoplastic and interstitial inflammatory infiltrate cells in gastric cancer [ J]. Folia Histochem Cytobiol, 2009, 47 (3) : 491- 496.
7Wilson 1M, Davies JJ, Weber M, et al. Epigenomics , mapping the methylome [J]. Cell Cycle, 2006, 5(2): 155-158.
8Roy R , Yang J, Moses MA. Matrix rretalloproteinases as novel biomarkers and potential therapeutic targets in human Cancer [ J] Clin Oncol, 2009, 27 ( 31 ) : 5287 -5297 .
9Sato N, Maehara N, Su GH, et al. Effects of 5 -aza-2' -deoxycytidine on matrix metallo- proteinase expression and pancreatic cancer cell invasiveness [ J]. J Nat! Cancer Inst , 2003, 95 (4) : 327-330.
10Roach HI, Yamada N, Cheung KS, et al. Association between the abnormal expression of matrix -degrading enzymes by human osteoarthritic chondrocytes and demethylation of specific CpG sites in the promoter regions[J]. Arthritis Rheum, 2005, 52 (10): 3110- 3124.
